Literature DB >> 29872480

The Use of Denosumab in a Nonagenarian with Primary Hyperparathyroidism.

Tamer Shalaby1, Samantha Anandappa2, Siva Sivappriyan3, Jesse Kumar1.   

Abstract

Denosumab is a monoclonal antibody which is currently licensed in the UK drug market for the prevention of skeletal-related events secondary to malignancy (excluding myeloma). This monoclonal antibody is a 6 monthly subcutaneous injection that works by lowering calcium levels. When used in a 90 year old patient with primary hyperparathyroidism it demonstrated a dramatic reduction in the calcium level which had proven difficult to reduce by bisphosphonates and who was not a candidate for surgical intervention.

Entities:  

Keywords:  Denosumab; hypercalcaemia; monoclonal antibody; primary hyperparathyroidism (pPTH); subcutaneous injection

Year:  2014        PMID： 29872480      PMCID： PMC5983085          DOI： 10.17925/EE.2014.10.02.151

Source DB:  PubMed          Journal:  Eur Endocrinol        ISSN： 1758-3772


  6 in total

1.  NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours.

Authors:  Anwar Jilani; Zoe Garrett; Frances Sutcliffe; Andrew Stevens
Journal:  Lancet Oncol       Date:  2012-12       Impact factor: 41.316

2.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Authors:  David H Henry; Luis Costa; Francois Goldwasser; Vera Hirsh; Vania Hungria; Jana Prausova; Giorgio Vittorio Scagliotti; Harm Sleeboom; Andrew Spencer; Saroj Vadhan-Raj; Roger von Moos; Wolfgang Willenbacher; Penella J Woll; Jianming Wang; Qi Jiang; Susie Jun; Roger Dansey; Howard Yeh
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

3.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

4.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Authors:  Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

5.  The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism.

Authors:  Inaam A Nakchbandi; Robert Lang; Barbara Kinder; Karl L Insogna
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

6.  Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.

Authors:  Mimi I Hu; Ilya Glezerman; Sophie Leboulleux; Karl Insogna; Rasim Gucalp; Waldemar Misiorowski; Bennett Yu; Wendy Ying; Rajul K Jain
Journal:  J Natl Cancer Inst       Date:  2013-08-29       Impact factor: 13.506
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.